Posted: April 2017 By Giorgio Vittorio Scagliotti, MD, PhD The ambition to personalize medicine is intrinsic to the mission of every individual physician with the twin goals of reducing drug-related […] Read more
Posted: February 2017 By Cynthia L. Kryder, MS Clinical trials are essential to the development of new, potentially lifesaving therapies for patients with cancer. Well-designed clinical trials contribute to medical […] Read more
Posted: February 2017 By Caicun Zhou, MD As part of an ongoing series, IASLC Lung Cancer News is exploring how drug approval processes differ country by country, and continent by […] Read more
Posted: February 2017 Q&A with with Ronan J. Kelly, MB BCh, MBA Q: What is the impetus for the development of clinical pathways? A: The incidence of cancer in the US […] Read more
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC Drug development has become a biomarker- driven process, necessitating new approaches and clinical trial designs. Speakers addressed these issues in the […] Read more
By Sanjay Popat, FRCP, PhD United Kingdom Healthcare System The United Kingdom (UK) has a unique healthcare system: the National Health Service (NHS), a publicly funded, singlepayer system. Founded by […] Read more
By Matteo Giaj Levra, MD, and Silvia Novello MD, PhD In September, the 2016 ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of metastatic nonsmall cell lung cancer (NSCLC) […] Read more
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published online in April 2013 the original “Molecular Testing […] Read more
By Erik J. MacLaren, PhD The table at right lists key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as of February 2016. These guidelines are not […] Read more